Skip to content
10-Q

Quarterly Report

Elevation Oncology, Inc.

0001558370-25-007801

← back to feed
Filed
May 15, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 9, 2025 59.22M sh
Shares Diluted Q1 2025 · Mar 31, 2025 59.17M sh
Shares Diluted restated Q1 2025 · Mar 31, 2024 51.81M sh
Stock Repurchased Q1 2025 · Mar 31, 2025 $17K
Stock Repurchased Q1 2025 · Mar 31, 2024 $26K
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$12.71M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$9.58M
Long Term Debt Q1 2025 · Mar 31, 2025 $31.25M
Long Term Debt Q1 2025 · Dec 31, 2024 $31.13M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $60.49M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $49.46M
Stockholders Equity Q1 2025 · Mar 31, 2025 $46.73M
Stockholders Equity Q1 2025 · Dec 31, 2024 $60.03M
Stockholders Equity Q1 2025 · Mar 31, 2024 $75.82M
Stockholders Equity Q1 2025 · Dec 31, 2023 $54.81M
Current Liabilities Q1 2025 · Mar 31, 2025 $4.24M
Current Liabilities Q1 2025 · Dec 31, 2024 $4.47M
Total Liabilities Q1 2025 · Mar 31, 2025 $35.49M
Total Liabilities Q1 2025 · Dec 31, 2024 $35.6M
Current Assets Q1 2025 · Mar 31, 2025 $82.19M
Current Assets Q1 2025 · Dec 31, 2024 $94.73M
Total Assets Q1 2025 · Mar 31, 2025 $82.22M
Total Assets Q1 2025 · Dec 31, 2024 $95.63M
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.24
Eps Diluted restated Q1 2025 · Mar 31, 2024 −$0.21
Eps Basic Q1 2025 · Mar 31, 2025 −$0.24
Eps Basic restated Q1 2025 · Mar 31, 2024 −$0.21
Sga Expense Q1 2025 · Mar 31, 2025 $3.97M
Sga Expense Q1 2025 · Mar 31, 2024 $3.86M
Rd Expense Q1 2025 · Mar 31, 2025 $6.88M
Rd Expense Q1 2025 · Mar 31, 2024 $6.01M
Net Income Q1 2025 · Mar 31, 2025 −$14.21M
Net Income Q1 2025 · Mar 31, 2024 −$10.71M
Operating Income Q1 2025 · Mar 31, 2025 −$14.22M
Operating Income Q1 2025 · Mar 31, 2024 −$9.87M